Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are widely used in Bulgaria to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The market for these drugs has been steadily growing in recent years due to various factors.
Customer preferences: Bulgarian customers prefer bronchodilator drugs that are effective and affordable. They also tend to prefer inhalers over other forms of bronchodilator drugs, as they are more convenient to use and provide faster relief.
Trends in the market: One of the major trends in the Bulgarian bronchodilator drugs market is the increasing use of combination therapies. These are drugs that combine two or more bronchodilators or other types of respiratory medication in a single inhaler. Combination therapies are becoming more popular because they can provide more effective relief for patients with severe respiratory conditions.Another trend in the market is the growing use of digital technologies to monitor and manage respiratory diseases. This includes the use of mobile apps and wearable devices that can track symptoms and provide feedback to patients and healthcare providers. Digital technologies are becoming increasingly important in the management of chronic respiratory diseases, and are likely to play a larger role in the Bulgarian market in the coming years.
Local special circumstances: Bulgaria has a high prevalence of respiratory diseases, particularly among older adults. This has led to a relatively large market for bronchodilator drugs, as well as other respiratory medications. The Bulgarian government has also implemented policies to improve access to healthcare services, which has helped to increase demand for these drugs.
Underlying macroeconomic factors: The Bulgarian economy has been growing steadily in recent years, which has led to increased spending on healthcare. This has helped to support the growth of the bronchodilator drugs market, as well as other healthcare sectors. Additionally, Bulgaria's membership in the European Union has helped to facilitate the import and export of pharmaceutical products, which has made it easier for companies to operate in the Bulgarian market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
